Received Jun 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
didn't respond to the vaccine; This non-serious case was reported by a consumer via sales rep and described the occurrence of therapy non-responder in a male patient who received HBV (Engerix B adult) for prophylaxis. Co-suspect products included HBV (Engerix B adult) for prophylaxis and HBV (Engerix B adult) for prophylaxis. On an unknown date, the patient received the 3rd dose of Engerix B adult, the 2nd dose of Engerix B adult and the 1st dose of Engerix B adult. On an unknown date, an unknown time after receiving Engerix B adult, Engerix B adult and Engerix B adult, the patient experienced therapy non-responder (Verbatim: didn't respond to the vaccine). The outcome of the therapy non-responder was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-JUN-2025 The reporter would like to know the rate of non-responsiveness to hepatitis b vaccine. He himself said he did not respond to the vaccine. For more information, please contact the field agent, the vaccine administration facility was the same as primary reporter.
Test Name: Serology test; Result Unstructured Data: (Test Result:negative,Unit:unknown,Normal Low:,Normal High:)